Moleculin Biotech, Inc. (MBRX): Nasdaq/NYSE listing notice — Moleculin Biotech receives Nasdaq delisting notice for failing minimum stockholders' equity rule

Moleculin Biotech, Inc.

Nasdaq notified Moleculin on May 23, 2025, that it does not meet Listing Rule 5550(b)(1) requiring $2.5M in stockholders' equity.
The company has 45 calendar days to submit a plan to regain compliance; if accepted, a 180-day extension may be granted.
Failure to regain compliance could lead to delisting from the Nasdaq Capital Market; no immediate effect on trading.
The company may appeal any adverse Staff determination to the Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does not h

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-018358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.